Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 7/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15000389 | 0.98 | NFE2L2 (0.66) | NFE2L2KMT2AMEN1HPGDGRM2 | |
| SCHEMBL15000480 | 0.92 | NFE2L2 (0.56) | NFE2L2KMT2AMEN1HPGDPSMB1 | |
| SCHEMBL18100900 | 0.86 | NFE2L2 (0.59) | NFE2L2KMT2AMEN1HPGDGRM2 | |
| SCHEMBL15472286 | 0.85 | NFE2L2 (0.51) | NFE2L2KMT2AMEN1HPGDKDM4E | |
| SCHEMBL18925952 | 0.84 | NFE2L2 (0.49) | NFE2L2KMT2AMEN1 | |
| SCHEMBL13439690 | 0.83 | FFAR1 (0.56) | NFE2L2KMT2AMEN1HPGD | |
| SCHEMBL2631350 | 0.82 | NFE2L2 (0.47) | NFE2L2KMT2AMEN1HRH3EPHX1 | |
| SCHEMBL20958147 | 0.81 | NFE2L2 (1.00) | NFE2L2HPGDGRM2HRH3 | |
| SCHEMBL35212115 | 0.81 | NFE2L2 (0.70) | NFE2L2KMT2AMEN1HPGDGRM2 | |
| SCHEMBL30674531 | 0.81 | NFE2L2 (0.70) | NFE2L2KMT2AMEN1HPGDGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2016-09-08 | — | — | US | disclosed |
| US-9382277-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | NFE2L2 2209/4885KMT2A 2493/4885MEN1 2624/4885 |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | NFE2L2 2209/4885KMT2A 2493/4885MEN1 2624/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | NFE2L2 2209/4885KMT2A 2493/4885MEN1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.